The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, NewAmsterdam Pharma Company NV’s stock clocked out at $21.50, up 6.07% from its previous closing price of $20.27. In other words, the price has increased by $6.07 from its previous closing price. On the day, 2.69 million shares were traded.
Ratios:
To gain a deeper understanding of NAMS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.08 and its Current Ratio is at 8.08. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $48.
On March 14, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $35.Scotiabank initiated its Sector Outperform rating on March 14, 2024, with a $35 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 04 ’25 when Kooij Louise Frederika bought 150,000 shares for $20.27 per share.
Douglas F Kling bought 500,000 shares of NAMS for $11,600,000 on Jan 27 ’25. On Jan 27 ’25, another insider, Mayur Somalya, who serves as the Affiliate of the company, bought 200,000 shares for $23.20 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 51.82 while its Price-to-Book (P/B) ratio in mrq is 3.07.
Stock Price History:
Over the past 52 weeks, NAMS has reached a high of $27.29, while it has fallen to a 52-week low of $15.19. The 50-Day Moving Average of the stock is -4.49%, while the 200-Day Moving Average is calculated to be 8.73%.
Shares Statistics:
A total of 108.06M shares are outstanding, with a floating share count of 56.66M. Insiders hold about 48.41% of the company’s shares, while institutions hold 47.77% stake in the company.
Earnings Estimates
The current rating of NewAmsterdam Pharma Company NV (NAMS) is the result of assessments by 8.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.37 and low estimates of -$0.5.
Analysts are recommending an EPS of between -$1.48 and -$2.01 for the fiscal current year, implying an average EPS of -$1.74. EPS for the following year is -$1.75, with 8.0 analysts recommending between -$1.19 and -$2.25.
